Comparing Rimegepant Nurtec ODT and Rizatriptan Maxalt MLT-ODT for Treating Acute Migraine in Adults Aged 18 to 65 in the Emergency Department

What this Trial Is About

Researchers are evaluating and comparing the pain relief effects and safety of two oral migraine treatments, Rimegepant Nurtec ODT and Rizatriptan Maxalt MLT-ODT, in adults experiencing acute migraine headaches. This randomized, double-blind trial is conducted in an urban emergency department setting with adult patients diagnosed with migraine without aura, seeking to determine which medication provides better pain relief within 60 and 120 minutes. Participants receive either Rimegepant 75 mg or Rizatriptan 10 mg orally disintegrating tablets during their emergency department visit. The study involves careful monitoring of headache intensity every 30 minutes for up to 120 minutes after medication. Patients who need additional pain relief after one hour may receive rescue medication as determined by their physician. The trial includes follow-up by phone 24 hours after discharge to assess headache status and treatment satisfaction. During the study, participants will rate their pain using a validated 11-point numerical scale and describe their headache severity and functional ability using standard categorical scales. Researchers will record demographic, medical, and vital sign data, and evaluate outcomes such as pain reduction at 60 minutes, use of rescue medication, sustained headache relief for 24 hours, and patient satisfaction with treatment. The total involvement includes the emergency visit and a phone follow-up 24 hours later.

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache